ライフサイエンスコーパス: coccidioidomycosis

1 for Lyme disease, giardia, and Valley Fever (coccidioidomycosis).

2 ation of a cellular immune response in human coccidioidomycosis.

3 inclusion in a vaccine candidate to prevent coccidioidomycosis.

4 s as well as from patients with disseminated coccidioidomycosis.

5 ine against C. posadasii in a mouse model of coccidioidomycosis.

6 posadasii) are the causative agents of human coccidioidomycosis.

7 n the donor lungs, leading to posttransplant coccidioidomycosis.

8 be incorporated into a human vaccine against coccidioidomycosis.

9 United States and is the causative agent of coccidioidomycosis.

10 y be useful in the treatment of disseminated coccidioidomycosis.

11 mitis, was investigated in a murine model of coccidioidomycosis.

12 the parental isolate in our murine model of coccidioidomycosis.

13 dies support rAg2/PRA vaccination to prevent coccidioidomycosis.

14 be essential components of a vaccine against coccidioidomycosis.

15 mmitis urease as a candidate vaccine against coccidioidomycosis.

16 e effective therapy for progressive forms of coccidioidomycosis.

17 rational target for therapy of disseminated coccidioidomycosis.

18 t sufficient to make C57BL mice resistant to coccidioidomycosis.

19 munoprotective capacity in a murine model of coccidioidomycosis.

20 nd is a valuable aid in the serodiagnosis of coccidioidomycosis.

21 antigen 2 (Ag2) gene vaccine in experimental coccidioidomycosis.

22 therapy could be used as adjunct therapy for coccidioidomycosis.

23 phic fungal pathogen that causes the disease coccidioidomycosis.

24 PRA as a candidate vaccine for prevention of coccidioidomycosis.

25 s a devastating complication of disseminated coccidioidomycosis.

26 ased the risk for being diagnosed with acute coccidioidomycosis.

27 examining the role of anti-Ag2 antibodies in coccidioidomycosis.

28 in prevention and early recognition of acute coccidioidomycosis.

29 a valuable diagnostic and prognostic aid in coccidioidomycosis.

30 somiasis, histoplasmosis, blastomycosis, and coccidioidomycosis.

31 cavitary pulmonary disease, and disseminated coccidioidomycosis.

32 tibodies and did not meet the definition for coccidioidomycosis.

33 l deaths (95% CrI, 700-1100) associated with coccidioidomycosis.

34 ilitate product development for treatment of coccidioidomycosis.

35 tain immunocompetent patients with pulmonary coccidioidomycosis.

36 r characterization of the natural history of coccidioidomycosis.

37 tigen detection for diagnosis of progressive coccidioidomycosis.

38 ct on outcomes among patients with pulmonary coccidioidomycosis.

39 ngitis (CM) is a devastating complication of coccidioidomycosis.

40 offer improved accuracy for the diagnosis of coccidioidomycosis.

41 olved, and 83% in disseminated and meningeal coccidioidomycosis.

42 gely derived from murine models of pulmonary coccidioidomycosis.

43 r characterization of the natural history of coccidioidomycosis.

44 duced the resistance of B6 mice to pulmonary coccidioidomycosis.

45 involved in MyD88-dependent Th17 immunity to coccidioidomycosis.

46 rst-in-class orphan product for treatment of coccidioidomycosis.

47 ses suggests potential benefit in refractory coccidioidomycosis.

48 e role of V/C salvage therapy for refractory coccidioidomycosis.

49 t report of an epitope-based vaccine against coccidioidomycosis.

50 active or occult infection can also transmit coccidioidomycosis.

51 ccine, are fully protected against pulmonary coccidioidomycosis.

52 immunotherapeutic protocols for treatment of coccidioidomycosis.

53 h prophylaxis did not experience reactivated coccidioidomycosis.

54 ive and IgG-negative EIA result did not have coccidioidomycosis.

55 EIA are thought to have a diagnosis of acute coccidioidomycosis.

56 ts for IgM among persons suspected of having coccidioidomycosis.

57 e in vitro testing of vaccine candidates for coccidioidomycosis.

58 rotects both BALB/c and C57BL/6 mice against coccidioidomycosis.

59 ilitate improved treatment and prevention of coccidioidomycosis.

60 tment course was complicated by disseminated coccidioidomycosis.

61 -month study of patients being evaluated for coccidioidomycosis, 1 or more serum samples were obtaine

62 elve received a diagnosis of acute pulmonary coccidioidomycosis, 17 received other diagnoses, and 17

63 ged > or =60 years with laboratory-confirmed coccidioidomycosis; 2 control groups were selected, the

64 zation (4% vs. 1%, p=0.004) and disseminated coccidioidomycosis (3% vs. 0%, p=0.006) were more freque

65 However, cough was more common with coccidioidomycosis (31.4%) and less common with histopla

66 However, cough was more common with coccidioidomycosis (31.4%) and less common with histopla

67 61 (1.3%) subsequently developed symptomatic coccidioidomycosis; 36/925 (3.9%) had coccidioidomycosis

68 f 47 transplant recipients with a history of coccidioidomycosis, 44 had quiescent infection at transp

69 Among 1,448 patients with pulmonary coccidioidomycosis, 659 (46%) received fluconazole.

70 stomycosis (2.6%), histoplasmosis (5.3%) and coccidioidomycosis (9.4%) than in influenza (18.5%) or p

71 tomycosis (2.6%), histoplasmosis (5.3%), and coccidioidomycosis (9.4%) than in patients with influenz

72 t assays with sera from patients with active coccidioidomycosis, a hyperimmune goat anti-Ag2 serum, a

73 P) antibody present in sera of patients with coccidioidomycosis, a reaction which has been used for s

74 Disseminated coccidioidomycosis affects the skin, central nervous sys

75 phylaxis effectively suppressed recrudescent coccidioidomycosis after solid organ transplantation for

76 stantially decreased the risk of reactivated coccidioidomycosis after transplantation in these patien

77 nfection, azoles suppressed any recrudescent coccidioidomycosis after transplantation.

78 action, PBMC from subjects with disseminated coccidioidomycosis also expressed less mRNA for IFN-gamm

79 Coccidioidomycosis (also known as San Joaquin Valley fev

80 t of each patient's individual circumstances.Coccidioidomycosis, also known as San Joaquin Valley fev

81 tistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward sli

82 An outbreak of coccidioidomycosis among 22 Navy SEALs occurred during t

83 of this study is to assess the incidence of coccidioidomycosis among lung transplant recipients rece

84 rophylaxis was associated with a low rate of coccidioidomycosis among lung transplant recipients resi

85 Because of the increase in incidence of coccidioidomycosis among the elderly in Arizona between

86 Coccidioidomycosis, an endemic fungal infection in the d

87 Coccidioidomycosis, an endemic fungal infection seen thr

88 Coccidioidomycosis, an infection endemic to the southwes

89 Serum samples from 103 cases of coccidioidomycosis and 373 controls were tested for IgG

90 /100 000 person-years for histoplasmosis and coccidioidomycosis and 50 cases/100 000 person-years for

91 transplant recipients are at risk of severe coccidioidomycosis and are given prophylaxis to mitigate

92 owed reactivity with sera from patients with coccidioidomycosis and elicited delayed-type footpad hyp

93 Ag nonresponsive patients with disseminated coccidioidomycosis and healthy nonimmune individuals.

94 een used for the diagnosis of other forms of coccidioidomycosis and meningitis caused by other mycose

95 th CD4+ and CD8+ T cells can protect against coccidioidomycosis and that TNF- alpha is a necessary co

96 ts to compare the development of symptomatic coccidioidomycosis and to describe its outcomes for pati

97 romising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.

98 ibody in 21 (95%) of 22 patients with active coccidioidomycosis and was without reactivity with sera

99 There were 79 749 histoplasmosis, 37 726 coccidioidomycosis, and 6109 blastomycosis diagnoses in

100 hreshold for histoplasmosis, 69% (35/51) for coccidioidomycosis, and 78% (40/51) for blastomycosis.

101 Persons with histoplasmosis, coccidioidomycosis, and blastomycosis are diagnosed in s

102 outcome was the incidence of histoplasmosis, coccidioidomycosis, and blastomycosis for each US county

103 Diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were defined by In

104 Blastomycosis, coccidioidomycosis, and histoplasmosis cause various sym

105 Vector- and waterborne diseases and coccidioidomycosis are all likely to be affected by a wa

106 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada).

107 after antigen stimulation from subjects with coccidioidomycosis as compared to those with another dia

108 be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving

109 At least 11 of these 49 patients had coccidioidomycosis as determined by culture or subsequen

110 onse in PBMC from patients with disseminated coccidioidomycosis as well as healthy nonimmune individu

111 Mortality due to coccidioidomycosis at last known follow up was significa

112 omatic coccidioidomycosis; 36/925 (3.9%) had coccidioidomycosis at screening (7, probable infection;

113 Mortality due to coccidioidomycosis at the last known follow-up was signi

114 Of the three with active coccidioidomycosis at transplantation, two were taking a

115 ofungin (V/C) salvage therapy for refractory coccidioidomycosis at two children's hospitals between J

116 e respiratory distress syndrome secondary to coccidioidomycosis because of the fear of enhancing fung

117 ed for identifying and managing asymptomatic coccidioidomycosis before patients began TNFi therapy.

118 large majority of patients with a history of coccidioidomycosis before transplantation.

119 A systematic estimate of coccidioidomycosis burden is needed to raise awareness a

120 ar Lv is responsible for early resistance to coccidioidomycosis but not for modulating the IL-10 and

121 cting CF antibody in sera from patients with coccidioidomycosis but was not specific to C. immitis, a

122 etection is the main method for diagnosis of coccidioidomycosis, but it has limitations.

123 ination may be a risk factor for reactivated coccidioidomycosis, but this finding was not statistical

124 dioides sp., the etiological agents of human coccidioidomycosis, but with a travel history including

125 We investigated secondary immunity against coccidioidomycosis by using gene expression microarrays.

126 We conclude that coccidioidomycosis can be caused by two distinct noninte

127 The single coccidioidomycosis case occurred 5 years posttransplant

128 Reports of coccidioidomycosis cases in Arizona have increased subst

129 ctional study developed models incorporating coccidioidomycosis cases reported to the National Notifi

130 [CrI], 206 000-360 000) incident symptomatic coccidioidomycosis cases were estimated in 2019.

131 Models estimated annual incident symptomatic coccidioidomycosis cases, hospitalizations, and deaths n

132 and March 15, 1994, 203 outbreak-associated coccidioidomycosis cases, including 3 fatalities, were i

133 Coccidioidomycosis causes a substantial disease burden i

134 Coccidioidomycosis (CM) is a common cause of community a

135 Coccidioidomycosis (CM) is a common cause of community-a

136 Coccidioidomycosis (CM) is common and important within e

137 d in samples from those with acute pulmonary coccidioidomycosis, compared with the other 2 groups (fo

138 Thoracic coccidioidomycosis complications include pleural space c

139 cal trials, and research on vaccines against coccidioidomycosis continues to advance.

140 Coccidioidomycosis continues to be a threat to military

141 on-central nervous system (CNS) disseminated coccidioidomycosis (DCM) has not been previously charact

142 entral nervous system (non-CNS) disseminated coccidioidomycosis (DCM) has not been previously charact

143 Refractory disseminated coccidioidomycosis (DCM) is a severe disease with limite

144 cavitary pulmonary disease, and disseminated coccidioidomycosis (DCM).

145 blood obtained from patients with pulmonary coccidioidomycosis demonstrated specific cellular immune

146 The outcome of coccidioidomycosis depends to a large extent on the effe

147 center to identify factors for recrudescent coccidioidomycosis (despite antifungal prophylaxis) afte

148 Only 8% of participants were aware of coccidioidomycosis, despite the majority having visited

149 Symptomatic coccidioidomycosis developed in 35/1025 (3.4%) unscreene

150 Disseminated coccidioidomycosis diagnosis is facilitated through reco

151 patients ages 18-64 with incident pulmonary coccidioidomycosis during 2017-2023 and continuous enrol

152 No case or control patients developed active coccidioidomycosis during the follow-up period.

153 ecipients who died or received treatment for coccidioidomycosis during the transplant admission, or w

154 BAL fluid from patients living in a coccidioidomycosis-endemic region of Arizona who were un

155 variation, and environmental factors impact coccidioidomycosis epidemiology and outcomes in South Am

156 nt outcomes and enhance our understanding of coccidioidomycosis epidemiology.

157 A major epidemic of coccidioidomycosis (etiologic agent, Coccidioides immiti

158 Children's Hospital Central California with coccidioidomycosis from 1 January 2010 to 1 September 20

159 and Drug Administration convened experts in coccidioidomycosis from academia, industry, patient grou

160 Elderly persons with coccidioidomycosis had spent significantly less time in

161 Development of a human vaccine against coccidioidomycosis has focused on recombinant T-cell-rea

162 Coccidioides posadasii in a murine model of coccidioidomycosis has led to the discovery of potential

163 The utility of this assay in coccidioidomycosis has not been previously studied.

164 data suggest that patients with disseminated coccidioidomycosis have a diminished T helper lymphocyte

165 No new treatments for coccidioidomycosis have been approved in the United Stat

166 Clinical and animal studies of coccidioidomycosis have demonstrated that activated CD4(

167 veolar lavage (BAL) fluid in acute pulmonary coccidioidomycosis have not been defined.

168 Coccidioidomycosis, histoplasmosis, and blastomycosis ar

169 sorbent assays using sera from patients with coccidioidomycosis, histoplasmosis, or blastomycosis.

170 is codes during 2016-2017 for blastomycosis, coccidioidomycosis, histoplasmosis, pneumonia (viral, ba

171 is codes during 2016-2017 for blastomycosis; coccidioidomycosis; histoplasmosis; pneumonia (viral, ba

172 Patients with coccidioidomycosis identified only by newer tests had fe

173 A North Carolinian developed fatal coccidioidomycosis immediately after bilateral lung tran

174 the estimated national burden of symptomatic coccidioidomycosis in 2019 was 10 to 18 times higher tha

175 as defined as laboratory-confirmed, incident coccidioidomycosis in a person infected with HIV for > o

176 ribe a case of life-threatening disseminated coccidioidomycosis in a previously healthy child.

177 Coccidioidomycosis in Arizona has increased.

178 (MR) and Dectin-2 in resistance to pulmonary coccidioidomycosis in C57BL/6 (B6) mice and in the inter

179 y was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons.

180 uary 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV)

181 a promising vaccine candidate for preventing coccidioidomycosis in humans or other animals.

182 near Tnfr1 are associated with resistance to coccidioidomycosis in mice.

183 nse and confers protection against pulmonary coccidioidomycosis in mice.

184 ns need to be aware of their higher risk for coccidioidomycosis in order to improve their chances of

185 Herein, we review available data on coccidioidomycosis in solid organ transplant recipients

186 We report an unusual case of coccidioidomycosis in the arm of a veterinary assistant

187 enic fungus that causes endemic and epidemic coccidioidomycosis in the deserts of North, Central, and

188 cal experience treating medically refractory coccidioidomycosis in the pediatric population with conc

189 We describe a case of coccidioidomycosis in which several unusual morphologic

190 rrent epidemics of San Joaquin Valley fever (coccidioidomycosis) in desert regions of the southwester

191 ntal studies indicate that prior symptomatic coccidioidomycosis induces immunity against subsequent i

192 atory distress syndrome owing to a fulminant coccidioidomycosis infection that responded to a short c

193 3%) additional patients developed "possible" coccidioidomycosis infections.

194 Coccidioidomycosis is a common cause of community-acquir

195 Coccidioidomycosis is a common fungal infection acquired

196 Coccidioidomycosis is a fungal disease associated with s

197 Coccidioidomycosis is a fungal disease endemic to the so

198 Coccidioidomycosis is a fungal infection endemic in the

199 Coccidioidomycosis is a fungal infection that is endemic

200 Coccidioidomycosis is a fungal infection with a range of

201 Coccidioidomycosis is a human respiratory disease that i

202 Coccidioidomycosis is a potentially life-threatening res

203 Coccidioidomycosis is a respiratory disease of humans ca

204 Coccidioidomycosis is a spectrum of diseases caused by t

205 Coccidioidomycosis is an airborne infection caused by th

206 Coccidioidomycosis is an endemic fungal infection of the

207 Coccidioidomycosis is an increasingly important health p

208 Coccidioidomycosis is an underrecognized fungal infectio

209 Extrathoracic dissemination of coccidioidomycosis is associated with a lack of cellular

210 identification of candidate vaccines against coccidioidomycosis is both efficient and productive.

211 Coccidioidomycosis is caused by the dimorphic fungus Coc

212 m vaccination, once an effective vaccine for coccidioidomycosis is developed.

213 The pathology of human coccidioidomycosis is granulomatous inflammation with ma

214 This study suggests that the risk of serious coccidioidomycosis is low among military personnel durin

215 Coccidioidomycosis is not reportable in all states, and

216 The spatial epidemiology of coccidioidomycosis is poorly understood due to irregular

217 Gastrointestinal coccidioidomycosis is uncommon, manifesting as peritonit

218 Coccidioidomycosis, listed as a priority mycosis by the

219 Uncommon coccidioidomycosis manifestations may simulate malignanc

220 Genitourinary coccidioidomycosis manifests as pyelonephritis or pelvic

221 Musculoskeletal coccidioidomycosis manifests with lytic bone lesions and

222 Chronic coccidioidomycosis manifests with nodules or cavities th

223 will be unfamiliar with how skin testing for coccidioidomycosis might be useful in patient management

224 Improved national reporting of cases of coccidioidomycosis might reduce diagnostic delays.

225 Groups were identified as non-disseminated coccidioidomycosis (non-DCM, 462 patients), DCM (44 pati

226 tional recommendations address management of coccidioidomycosis occurring for special at-risk populat

227 Currently available diagnostics for coccidioidomycosis offer qualitative results that can su

228 Patients with pulmonary coccidioidomycosis often experience prolonged symptoms l

229 Central nervous system coccidioidomycosis often manifests with basilar meningit

230 mals and can cause diverse manifestations of coccidioidomycosis or Valley fever (VF).

231 Coccidioides posadasii causes coccidioidomycosis, or Valley fever, in the endemic regi

232 Coccidioidomycosis, or Valley fever, is an infectious di

233 This is the first report of a coccidioidomycosis outbreak following an earthquake.

234 nd timing of cases strongly suggest that the coccidioidomycosis outbreak in Ventura County was caused

235 ed to 1.7 in DTH-negative donors with active coccidioidomycosis (P = 0.03).

236 istorical Veterans Affairs (VA)-Armed Forces coccidioidomycosis patient group provides a unique cohor

237 The historical VA-Armed Forces coccidioidomycosis patient group provides a unique cohor

238 a retrospective study of 531 VA-Armed Forces coccidioidomycosis patients diagnosed between 1955-1958

239 ing the purified rCts1(Ur), 74 out of the 77 coccidioidomycosis patients examined (96.1%) were positi

240 -linked immunosorbent assays of sera from 28 coccidioidomycosis patients.

241 e key topics concerning drug development for coccidioidomycosis presented by speakers and panelists d

242 Northeastern Brazil presents a distinctive coccidioidomycosis profile, with armadillo hunters facin

243 eed for a rapid and safe means of diagnosing coccidioidomycosis prompted us to develop a real-time PC

244 asis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was assoc

245 Coccidioidomycosis ranges from a mild to a severe infect

246 large-volume transplant center in an endemic coccidioidomycosis region to compare outcomes of non-lun

247 eiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence i

248 The care of primary pulmonary coccidioidomycosis remains challenging.

249 The in situ immunologic response in human coccidioidomycosis remains undefined.

250 Coccidioidomycosis reported to public health surveillanc

251 of 0.16 +/- 0.04, patients with disseminated coccidioidomycosis showed a mean response of 0.69 +/- 0.

252 inum, Pleura, Tracheobronchial Tree, Fungus, Coccidioidomycosis, Spherules, Cavity, Nodule, Endemic,

253 of lists of persons with negative serologic coccidioidomycosis tests (laboratory-negative controls,

254 ly higher in DTH-positive donors with active coccidioidomycosis than in healthy, nonimmune controls (

255 d cohort was more likely to have symptomatic coccidioidomycosis than the screened cohort (35/1025 vs

256 sed by all biopsied lesions of patients with coccidioidomycosis that we examined, whether localized t

257 f the 22 men had serologic evidence of acute coccidioidomycosis, the highest attack rate ever reporte

258 Like most patients with disseminated coccidioidomycosis, this child had no genomic evidence o

259 ced protective immunity against experimental coccidioidomycosis through the induction of Th1-associat

260 99 and June 2009, 100 patients with previous coccidioidomycosis underwent solid organ transplantation

261 fungus responsible for a recent epidemic of coccidioidomycosis (Valley fever) in California.

262 ue is pervasive in the southwestern US where coccidioidomycosis (Valley Fever) is endemic.

263 Coccidioidomycosis (Valley fever) occurs when animals an

264 rmation of the importance of B cells against coccidioidomycosis was achieved by demonstrating that va

265 the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with infla

266 Given the patients' lack of recent travel, coccidioidomycosis was not suspected, leading to delays

267 Serology for coccidioidomycosis was positive in six patients.

268 Coccidioidomycosis was recognized or considered in only

269 d for 72 h from 8 subjects with disseminated coccidioidomycosis was significantly less than that from

270 going transplantation in an area endemic for coccidioidomycosis, we recommend routine evaluation for

271 are required for vaccine-induced immunity to coccidioidomycosis, we used a temperature-sensitive muta

272 -cause mortality, and mortality secondary to coccidioidomycosis were assessed and compared between gr

273 l-cause mortality and mortality secondary to coccidioidomycosis were assessed and compared between gr

274 Thirteen cases of documented coccidioidomycosis were associated with TNF alpha antago

275 idence suggest that 3 individuals with acute coccidioidomycosis were exposed in Washington State, sig

276 Cases of coccidioidomycosis were identified and reviewed from amo

277 Nine children with refractory coccidioidomycosis were treated with V/C salvage therapy

278 tegies, and future diagnostic directions for coccidioidomycosis, which is expected to become more pre

279 ne responses from patients with disseminated coccidioidomycosis who are nonresponsive to coccidioidal

280 a retrospective review of all patients with coccidioidomycosis who underwent solid organ transplanta

281 he medical records of 47 patients with prior coccidioidomycosis who underwent solid organ transplanta

282 s among dogs-which are highly susceptible to coccidioidomycosis, widespread across the US, and have l

283 ent of the ability to control the problem of coccidioidomycosis will require research into the molecu

284 We investigated a case of disseminated coccidioidomycosis with hypercalcemia.

285 The primary outcome was proven or probable coccidioidomycosis with new asymptomatic seropositivity

286 of TNFi recipients screened for asymptomatic coccidioidomycosis with those of unscreened patients to

287 Screening for asymptomatic coccidioidomycosis within a Coccidioides-endemic area al